Ghrelin and insulin therapies, while showing potential in regard to improving muscle function and protein synthesis, may pose risks, with insulin linked to poorer outcomes in heart failure (HF) patients with diabetes [134]. The gene discussed is INS; the disease is diabetes mellitus.